127 related articles for article (PubMed ID: 18042935)
41. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
[TBL] [Abstract][Full Text] [Related]
42. [Breast ductal carcinoma in situ. The clinical image in the mammogram].
Mallek R; Mostbeck GH; Czerwenka K; Fitzal P; Wolf G
Rofo; 1994 Jan; 160(1):30-4. PubMed ID: 8305689
[TBL] [Abstract][Full Text] [Related]
43. Bilateral breast cancer: early detection with mammography.
Roubidoux MA; Helvie MA; Lai NE; Paramagul C
Radiology; 1995 Aug; 196(2):427-31. PubMed ID: 7617856
[TBL] [Abstract][Full Text] [Related]
44. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project.
Ng EH; Ng FC; Tan PH; Low SC; Chiang G; Tan KP; Seow A; Emmanuel S; Tan CH; Ho GH; Ng LT; Wilde CC
Cancer; 1998 Apr; 82(8):1521-8. PubMed ID: 9554530
[TBL] [Abstract][Full Text] [Related]
45. Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy.
Sharpe KH; McClements P; Clark DI; Collins J; Springbett A; Brewster DH
Eur J Cancer; 2010 Mar; 46(5):937-43. PubMed ID: 20122823
[TBL] [Abstract][Full Text] [Related]
46. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
Suzuki R; Ye W; Rylander-Rudqvist T; Saji S; Colditz GA; Wolk A
J Natl Cancer Inst; 2005 Nov; 97(21):1601-8. PubMed ID: 16264180
[TBL] [Abstract][Full Text] [Related]
47. [Contribution of mammography and echography to the diagnosis of breast cancer in Dakar: apropos of 25 cases].
Diop-Ba S; Badiane M; Niang EH; Ly Ba A; Alfidja A; Favre Y
Dakar Med; 1997; 42(2):114-7. PubMed ID: 9827132
[TBL] [Abstract][Full Text] [Related]
48. Association of estrogen receptors with parenchymal pattern at mammography.
Ciatto S; Cecchini S; Iossa A; Grazzini G; Messeri G; Valenti L; Nunzi G; Bartolucci R; Di Costanzo F
Radiology; 1989 Mar; 170(3 Pt 1):695-7. PubMed ID: 2916023
[TBL] [Abstract][Full Text] [Related]
49. Disentangling the roles of mammographic screening and HRT in recent breast cancer incidence trends in italy by analyses based on calendar time and time since screening activation.
Crocetti E; Buzzoni C; Falcini F; Cortesi L; De Lisi V; Ferretti S; Tumino R; Russo A; Paci E
Breast J; 2010; 16(4):350-5. PubMed ID: 20443789
[TBL] [Abstract][Full Text] [Related]
50. Incidence of and treatment for ductal carcinoma in situ of the breast.
Ernster VL; Barclay J; Kerlikowske K; Grady D; Henderson C
JAMA; 1996 Mar; 275(12):913-8. PubMed ID: 8598618
[TBL] [Abstract][Full Text] [Related]
51. Influence of hormone replacement therapy on the accuracy of screening mammography.
Vernet Mdel M; Checa MA; Macià F; Casamitjana M; Carreras R
Breast J; 2006; 12(2):154-8. PubMed ID: 16509841
[TBL] [Abstract][Full Text] [Related]
52. High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital.
Ly M; Antoine M; Dembélé AK; Levy P; Rodenas A; Touré BA; Badiaga Y; Dembélé BK; Bagayogo DC; Diallo YL; Koné AA; Callard P; Bernaudin JF; Diallo DA
Oncology; 2012; 83(5):257-63. PubMed ID: 22964749
[TBL] [Abstract][Full Text] [Related]
53. Reassessment of breast cancers missed during routine screening mammography: a community-based study.
Yankaskas BC; Schell MJ; Bird RE; Desrochers DA
AJR Am J Roentgenol; 2001 Sep; 177(3):535-41. PubMed ID: 11517043
[TBL] [Abstract][Full Text] [Related]
54. Assessment of potential risk factors for breast cancer in a population in Southern Brazil.
Breyer JZ; Wendland EM; Kops NL; Caleffi M; Hammes LS
Breast Cancer Res Treat; 2018 May; 169(1):125-131. PubMed ID: 29344741
[TBL] [Abstract][Full Text] [Related]
55. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
[TBL] [Abstract][Full Text] [Related]
56. Breast cancer decline mirrors fall in hormone use, spurs both debate and research.
McNeil C
J Natl Cancer Inst; 2007 Feb; 99(4):266-7. PubMed ID: 17312300
[No Abstract] [Full Text] [Related]
57. Postmenopausal hormone therapy and prevalent round screening mammography.
Sweeney KJ; Boran S; Fitzpatrick P; Merrigan AB; Moran R; Flanagan F; Kerin MJ
Int J Cancer; 2009 Mar; 124(6):1490-1. PubMed ID: 19065663
[No Abstract] [Full Text] [Related]
58. [Is estrogen therapy of significance for the incidence of breast cancer?].
Bakken K
Tidsskr Nor Laegeforen; 2004 Nov; 124(21):2801; author reply 2801. PubMed ID: 15534689
[No Abstract] [Full Text] [Related]
59. Female breast cancer.
Paci E; Pannelli F
Epidemiol Prev; 2004; 28(2 Suppl):64-7. PubMed ID: 15281608
[TBL] [Abstract][Full Text] [Related]
60. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias.
Joffe MM; Byrne C; Colditz GA
Epidemiology; 2001 Jul; 12(4):429-38. PubMed ID: 11416781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
